Good MorningEquities began the week on stable footing despite the previous week's large decline and the upcoming FOMC announcement on Wednesday. The Fed is expected to raise interest rates by 75 basis points on Wednesday and provide an outlook for the future of Fed policy. It is largely believed the Fed will continue to raise rates into the beginning of 2023 but at a much slower pace than what it has set so far. The risk is that inflation data will continue to accelerate as it has and push the Fed into ramping its posture once again.
On the economic front, the NAHB home builders survey declined to a new low as demand and traffic dry up. The news is only the latest in a string of poor housing data that points to a major contraction in the industry and one that will have rippling effects throughout the economy. Also on tap this week is a read on building permits and housing starts as well as existing home sales and the Index of Leading Indicators. Featured: Make 22x more from this summer’s Bitcoin boom (Ad) 
|
Markets | | | Database and cloud solutions provider Oracle (NASDAQ: ORCL) stock got smoked on its fiscal Q1 2023 earnings report. Shares were holding up relatively well until the Company revealed the extent of damage from FX related headwinds. Up until 2022, FX headwinds didn’t really impact stocks too much... Read the Full Story |
|
From Our Partners | | The media and financial pundits are all misreading Trump’s actions.
They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals…
They think his involvement in Ukraine is just another resource grab…
They think his tariffs will wreck the economy…
But they’re all missing the bigger picture. | | This is fast becoming the world’s most sought-after resource. |
|
Politics | | | The buck isn’t stopping.
The value of the U.S. dollar has been on a tear for more than a year against everything from the British pound across the Atlantic to the South Korean won across the Pacific.
After rising again Friday, the dollar is near its highest level in m... Read the Full Story |
|
Markets | | |
McDonald’s continues to be able to deliver growth
McDonald’s goes about its business ringing up sales to value-minded eaters
McDonald’s has a steady history of quarterly dividend distributions
Just like you know what you’re getting when you order the number 5 value m... Read the Full Story |
|
From Our Partners | | Often, investors will overlook stocks just because they're cheap.
It's a common thought that a cheap price tag means that something must be wrong with the company.
But this couldn't be further from the case in many instances. | | Get your FREE look at these THREE companies right here. |
|
Politics | | | JBS has agreed to pay $20 million to settle a lawsuit with consumers that accused the giant meat producer of conspiring with other meat companies to inflate the price of pork.
The latest meat-industry settlement will likely reinforce concerns that the White House, members of Congress ... Read the Full Story |
|
Politics | | | A parts shortage that has thousands of Ford's most-profitable vehicles sitting on lots waiting to be fully assembled has forced the automaker to slash its third-quarter earnings forecast.
Ford said Monday that it expects to have 40,000 to 45,000 unfinished vehicles on its hands when t... Read the Full Story |
|
From Our Partners | | Bitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs.
At first glance, that might seem like great news for regular investors.
More demand, higher prices, right?
But this isn’t the start of a new bull market…
It’s the start of a takeover. | | Click here to learn the entire strategy for free. |
|
Politics | | | Russian President Vladimir Putin vowed Friday to press his attack on Ukraine despite Ukraine's latest counteroffensive and warned that Moscow could ramp up its strikes on the country's vital infrastructure if Ukrainian forces target facilities in Russia.
Speaking to reporters Friday a... Read the Full Story |
|
Markets | | |
The market for Autozone (NYSE: AZO) stock pulled back from a fresh all-time high ahead of the FQ4 earnings release because there was cause for concern. Not only was the stock trading at an above-average P/E for the S&P 500 (NYSEARCA: SPY) and well above its peer Advance Auto Parts (NYSE: AAP) ... Read the Full Story |
|
Politics | | | The European Union’s executive branch recommended Sunday that the bloc suspend around 7.5 billion euros (dollars) in funding to Hungary over concerns about democratic backsliding and the possible mismanagement of EU money.
The European Commission, which proposes the bloc's laws and en... Read the Full Story |
|
Stocks | | |
Lucid is in a better financial position than most upstart EV players
The near-term headwinds should matter little in the long haul
Lucid noted that its liquidity position will keep it running well into 2023
Like most electric vehicle plays, Lucid Group, Inc. (NASDAQ: LCID) has had its shar... Read the Full Story |
|
Markets | | |
FedEx (NYSE: FDX) fired a warning shot the market needs to pay attention to when it prereleasedQ3 earnings but there is more to the story than what the headlines are screaming. FedEx is predicting a global recession in 2023 but the 20% decline in share prices is already offering a buying opportuni... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. | | View Today's Stock Pick |
|
